Group 1 - Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class therapies for autoimmune diseases and cancer [3] - The company will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, featuring CEO Nadim Ahmed and CMO Jeffrey Jones [1] - The fireside chat will be accessible via a webcast on the company's investor relations website [2] Group 2 - Cullinan Therapeutics leverages expertise in T cell engagers, which are established in oncology and are now being advanced into autoimmune diseases [3] - The company aims to deliver new standards of care for patients through a clinical-stage pipeline built on rigorous scientific approaches and purposeful innovation [3]

Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Core Viewpoint - ADMA Biologics, Inc. will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a conference call to discuss these results and company updates [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM, and NABI-HB, aimed at treating immune deficiencies and preventing certain infectious diseases [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Cytokinetics, Incorporated (NASDAQ:CYTK) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the fifteen best healthcare stocks on our list. TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 results to account for t ...

SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, today announced a definitive licensing agreement for DynaShield™ technology. The deal valued at up to $500 million grants Bio Usawa exclusive, worldwide rights to use and sublicense the DynaShield™ technology across its portfolio and in third-party biologic and vaccine products, enabling broad com ...

Core Viewpoint - HCW Biologics Inc. has announced a follow-on offering of 2,477,292 units at a price of $0.6055 per unit, aimed at funding clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of units that include one share of common stock (or pre-funded warrant) and one warrant, each with an exercise price of $0.6055, exercisable upon shareholder approval [1]. - The gross proceeds from the offering are expected to be approximately $1.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about February 19, 2026, subject to customary closing conditions [1]. Group 2: Existing Warrants - The company has negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, pending shareholder approval [3]. Group 3: Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies targeting chronic inflammation and related diseases [6]. - The lead product candidate, HCW9302, is being evaluated in a Phase 1 clinical trial for autoimmune diseases [7]. - The company has developed over 50 molecules using its TRBC platform, which aims to create immunotherapeutics for various disease indications, including cancer and autoimmune diseases [6][7].

Core Viewpoint - Telix Pharmaceuticals has submitted a marketing authorization application (MAA) in Europe for TLX101-Px, an imaging candidate for glioma, aiming to enhance patient access to advanced brain imaging [1][2]. Group 1: Regulatory Submission - The European submission for TLX101-Px was expedited to align with the U.S. FDA package, covering major European markets [2]. - A New Drug Application (NDA) for TLX101-Px will follow the European submission [2]. Group 2: Clinical Need and Product Development - There is currently no commercially available product in Europe for glioma imaging that ensures consistent quality and access, highlighting an acute need for TLX101-Px [3][5]. - TLX101-Px aims to differentiate between progressive glioma and treatment-related changes, with potential future indications [3]. - TLX101-Px is also being developed as a tool for patient selection and response assessment for Telix's glioblastoma therapy candidate TLX101-Tx, which is in Phase 3 trials [3]. Group 3: Market Context - Approximately 67,500 brain and central nervous system tumors are diagnosed annually in Europe, with gliomas making up about 30% of these cases [5]. - Gliomas are the most common primary brain tumors, and there is a critical need for improved diagnosis and management, especially in post-treatment settings [5]. Group 4: Product Characteristics - TLX101-Px targets L-type amino acid transporters (LAT1 and LAT2) and is intended to be a complementary diagnostic agent to TLX101-Tx [6]. - The proposed brand name for TLX101-Px in relevant European markets is "Pixlumi®," pending regulatory approval [7]. Group 5: Company Overview - Telix Pharmaceuticals is focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, with operations in multiple countries including Australia, the U.S., and Europe [8].

As filed with the Securities and Exchange Commission on February 17, 2026 Washington, D.C. 20549 Registration No. 333- FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion Dr ...

Company Overview - Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides secured loans to venture capital and private equity-backed companies, as well as publicly traded companies in technology, life sciences, healthcare information and services, and sustainability industries [1][2] - The company is externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, which specializes in private credit markets across various strategies [1] Financial Results Announcement - Horizon Technology Finance plans to release its financial results for the fourth quarter ended December 31, 2025, on March 3, 2026, after market close [1] - A conference call to discuss these results is scheduled for March 4, 2026, at 9:00 a.m. ET, featuring remarks from key executives including the CEO, Senior VP and Chief Investment Officer, and Executive VP and CFO [1] Recent Financial Activities - The company has provided a $50 million venture loan facility to Pelthos Therapeutics Inc., with an initial funding of $30 million and up to $20 million available for future growth [1] - Horizon Technology Finance has priced a registered direct offering of $57.50 million aggregate principal amount of 7.00% Notes due 2028, which will mature on December 15, 2028 [1] Monthly Distributions - The board of directors has declared monthly cash distributions for January, February, and March 2026, totaling $0.33 per share [2]

Core Viewpoint - Nuvation Bio Inc. will report its financial results for Q4 and the full year of 2025 on March 2, 2026, and will provide a business update during a conference call [1]. Company Overview - Nuvation Bio is a global oncology company focused on addressing significant challenges in cancer treatment, aiming to develop therapies that positively impact patients' lives [1]. - The company's diverse pipeline includes: - Taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor - Safusidenib, a brain-penetrant IDH1 inhibitor - NUV-868, a BD2-selective BET inhibitor - An innovative drug-drug conjugate (DDC) program [1]. Event Details - The conference call and webcast will take place on March 2, 2026, at 4:30 p.m. ET, and both investors and the public are invited to participate [1]. - Participants can access the live conference call by dialing +1 833-470-1428 (U.S. toll-free) and entering access code 833155 [1]. - An archived recording of the event will be available on Nuvation Bio's website for 90 days following the event [1].